Halozyme Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell HALO and other ETFs, options, and stocks.

About HALO

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. 

CEO
Helen I. Torley
CEOHelen I. Torley
Employees
350
Employees350
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
350
Employees350

HALO Key Statistics

Market cap
9.61B
Market cap9.61B
Price-Earnings ratio
17.07
Price-Earnings ratio17.07
Dividend yield
Dividend yield
Average volume
2.23M
Average volume2.23M
High today
$81.50
High today$81.50
Low today
$78.61
Low today$78.61
Open price
$78.78
Open price$78.78
Volume
2.25M
Volume2.25M
52 Week high
$81.50
52 Week high$81.50
52 Week low
$47.50
52 Week low$47.50

Stock Snapshot

With a market cap of 9.61B, Halozyme Therapeutics(HALO) trades at $81.50. The stock has a price-to-earnings ratio of 17.07.

On 2026-02-07, Halozyme Therapeutics(HALO) stock traded between a low of $78.61 and a high of $81.50. Shares are currently priced at $81.50, which is +3.7% above the low and 0.0% below the high.

Halozyme Therapeutics(HALO) shares are trading with a volume of 2.25M, against a daily average of 2.23M.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $81.50 at its peak.

During the past year, Halozyme Therapeutics(HALO) stock moved between $47.50 at its lowest and $81.50 at its peak.

HALO News

Investor's Business Daily 3d
Dow Jones Leader Cisco, Halozyme, Toll Brothers In Or Near Buy Zones

Stocks Near A Buy Zone Dow Jones Leader Cisco, Halozyme, Toll Brothers In Or Near Buy Zones Licensing As the Dow Jones Industrial Average and other stock indexe...

Dow Jones Leader Cisco, Halozyme, Toll Brothers In Or Near Buy Zones
Simply Wall St 4d
Halozyme Therapeutics Is Up 6.6% After Lifting Guidance And Expanding ENHANZE Beyond Oncology

In late January 2026, Halozyme Therapeutics raised its 2026 revenue guidance to a range of US$1.71 billion to US$1.81 billion and projected 2025 revenue between...

Halozyme Therapeutics Is Up 6.6% After Lifting Guidance And Expanding ENHANZE Beyond Oncology
Simply Wall St 7d
Is Halozyme Therapeutics Still Attractive After Recent Drug Delivery Partnership-Driven Gains

Wondering whether Halozyme Therapeutics at US$71.71 still offers value, or if most of the opportunity is already priced in? This article walks through that ques...

Is Halozyme Therapeutics Still Attractive After Recent Drug Delivery Partnership-Driven Gains

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
30%
Sell
10%

People also own

Based on the portfolios of people who own HALO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.